One patient with advanced lung adenocarcinoma developed refractory hypertension after 19 months of treatment with bevacizumab and afatinib, the clinical pharmacist analyzed the patient's medication, and consulted the relevant literature, considering that the patient's refractory hypertension was related to bevacizumab and sleep difficulties. Because of the patient's proteinuria and the fact that the patient's blood pressure was not controlled below 130/80  mmHg, it was recommended that bevacizumab should be suspended, and the doctor accepted the recommendation. Through multiple adjustments to the antihypertensive regimen (nifedipine controlled-release, sacubitril/valsartan, metoprolol, indapamide) and sleep improvement (mirtazapine, lorazepam). The patient's sleep duration was extended to 4-5 hours, blood pressure was controlled below 130/80 mmHg, and bevacizumab treatment was resumed. In this case, the clinical pharmacist participated in the patient's drug treatment process, assisted the doctor in the adjustment of the individualized treatment plan for special populations, and promoted the patient's rational drug use.

1.Dong M, Wang R, Sun P, et al. Clinical significance of hypertension in patients with different types of cancer treated with antiangiogenic drugs[J]. Oncol Lett, 2021, 21(4): 315. DOI: 10.3892/ol.2021.12576.

2.中国抗癌协会整合肿瘤心脏病学分会, 《肿瘤相关高血压整合管理中国专家共识》专家组. 肿瘤相关高血压整合管理中国专家共识（2024年版）[J]. 中国肿瘤临床, 2024, 51(19): 993-1002. [Society of Integrative Cardio-Oncology, China Anti-Cancer Association, Expert Panel on Chinese Expert Consensus on Integrated Management of Cancer-Related Hypertension.Chinese expert consensus on integrated management of cancer-related hypertension (2024 version)[J]. Chinese Journal of Clinical Oncology, 2024, 51(19): 993-1002.] DOI: 10.12354 /j.issn. 1000-8179. 2024.20241244.

3.Quintanilha JCF, Wang J, Sibley AB, et al. Bevacizumab-induced hypertension and proteinuria: a genome-wide study of more than 1 000 patients[J]. Br J Cancer, 2022, 126(2): 265-274. DOI: 10.1038/s41416-021-01557-w.

4.颜楠, 徐文俊, 陈旭, 等. 回顾性分析贝伐珠单抗致高血压等重要不良反应[J]. 药学与临床研究, 2023, 31(2): 164-167. [Yan N, Xu WJ, Chen X, et al. Retrospective analysis of hypertension and other important adverse drug reactions induced by bevacizumab[J]. Pharmaceutical and Clinical Research, 2023, 31(2): 164-167.] DOI: 10.13664/j.cnki.pcr.2023.02.015.

5.中国高血压防治指南修订委员会, 高血压联盟（中国）, 中国医疗保健国际交流促进会高血压病学分会, 等. 中国高血压防治指南（2024年修订版）[J]. 中华高血压杂志（中英文）, 2024, 32(7): 603-700. DOI: 10.16439/j.issn.1673-7245.2024. 07.002.

6.魏丹丹, 刘文强, 黄珊. 1例难治性高血压合并肾功能不全患者的降压治疗[J]. 医药导报, 2022, 41(8): 1216-1220. [Wei DD, Liu WQ, Huang S. Antihypertensive treatment in a patient with refractory hypertension and renal insufficiency[J]. Herald of Medicine, 2022, 41(8): 1216-1220.] DOI: 10.3870/j.issn.1004-0781.2022.08.023.

7.中国医疗保健国际交流促进会高血压分会, 中国医师协会心血管分会, 中国高血压联盟, 等. 沙库巴曲缬沙坦在高血压患者临床应用的中国专家建议[J]. 中华高血压杂志, 2021, 29(2): 108-114. DOI: 10.16439/j.issn.1673-7245.2021.02.003.

8.Lin DS, Wang TD, Buranakitjaroen P, et al. Angiotensin receptor neprilysin inhibitor as a novel antihypertensive drug: evidence from Asia and around the globe[J]. J Clin Hypertens (Greenwich), 2021, 23(3): 556-567. DOI: 10.1111/jch.14120.

9.Li W, Gong M, Yu Q, et al. Efficacy of angiotensin receptor neprilysin inhibitor in Asian patients with refractory hypertension[J]. J Clin Hypertens(Greenwich), 2022, 24(4): 449-456. DOI: 10.1111/jch.14454.

10.王欢, 马松涛, 肖洪涛, 等. 贝伐珠单抗相关性高血压的研究现状[J]. 中国临床药理学杂志, 2024, 40(5): 763-767. [Wang H, Ma ST, Xiao HT, et al. Research status of bevacizumab associated hypertension[J]. Chinese Journal of Clinical Pharmacology, 2024, 40(5): 763-767.] DOI: 10.13699/ j.cnki.1001-6821.2024.05.028.

11.Camarda N, Travers R, Yang VK, et al. VEGF receptor inhibitor-induced hypertension: emerging mechanisms and clinical implications[J]. Curr Oncol Rep, 2022, 24(4): 463-474. DOI: 10.1007/s11912-022-01224-0.

12.Li C, Ma L, Wang Q, et al. Rho kinase inhibition ameliorates vascular remodeling and blood pressure elevations in a rat model of apatinib-induced hypertension[J]. J Hypertens, 2022, 40(4): 675-684. DOI: 10.1097/HJH.0000000000003060.

13.Versmissen J, van Doorn L, Mirabito Colafella KM, et al. Sunitinib-induced blood pressure rise does not involve aldosterone: observations in a patient after bilateral adrenalectomy[J]. J Hypertens, 2018, 36(11): 2279-2280. DOI: 10.1097/HJH.0000000000001894.

14.《难治性高血压血压管理中国专家共识》撰写工作组. 难治性高血压血压管理中国专家共识[J]. 中华高血压杂志（中英文）, 2024, 32(8): 704-709, 700. DOI: 10.16439/j.issn.1673- 7245.2024.08.002.

15.Mittal S, Jain P, Sharma R, et al. Approaches in managing resistant hypertension: a review[J]. Cureus, 2024, 16(4): e57804.DOI: 10.7759/cureus.57804.

16.韩旭, 任洁. 成人精神压力相关高血压研究进展[J]. 中华高血压杂志（中英文）, 2024, 32(3): 226-230. [Han X, Ren J. Advances in adult psychosocial stress-related hypertension[J]. Chinese Journal of Hypertension, 2024, 32(3): 226-230.] DOI: 10.16439/j.issn.1673-7245.2024.03.006.

17.DeLalio LJ, Sved AF, Stocker SD. Sympathetic nervous system contributions to hypertension: updates and therapeutic relevance[J]. Can J Cardiol, 2020, 36(5): 712-720. DOI: 10.1016/j.cjca.2020.03.003.

18.梁嘉琪, 卢静, 金霄, 等. 老年高血压睡眠障碍的影响因素及干预策略[J]. 中西医结合心脑血管病杂志, 2022, 20(18): 3349-3352. [Liang JQ, Lu J, Jin X, et al. Factors and intervention strategies of sleep disorders in elderly hypertensive patients[J]. Chinese Journal of Integrative Medicine on Cardio/Cerebrovascular Disease, 2022, 20(18): 3349-3352.] DOI: 10.12102/j.issn.1672-1349.2022.18.014.

19.Hendriksen LC, Omes-Smit G, Koch BCP, et al. Sex-based difference in the effect of metoprolol on heart rate and bradycardia in a population-based setting[J]. J Pers Med, 2022, 12(6): 870.DOI: 10.3390/jpm12060870.

20.Li ZH, Huang QM, Gao X, et al. Healthy sleep associated with lower risk of hypertension regardless of genetic risk: a population-based cohort study[J]. Front Cardiovasc Med, 2021, 8: 769130.DOI: 10.3389/fcvm.2021.769130.

21.国家卫生计生委合理用药专家委员会, 中国医师协会高血压专业委员会. 高血压合理用药指南（第2版）[J]. 中国医学前沿杂志（电子版）, 2017, 9(7): 28-126. DOI: 10.12037/YXQY.2017.07-07.